Market Introduction
Kidney disease is also known as renal disease. It is caused due to the malfunctioning of the kidney. There are various types of kidney diseases including kidney stones, glomerulonephritis, urinary tract infections, and others. For the treatment and diagnosis of these types of diseases, different global and regional players are offering various products and services.
Market Overview and Dynamics
TheAsia Pacifickidney disease market is expected to reach US$ 37,204.4 million in 2027 from US$ 21,930.1million in 2019. The market is estimated to grow with a CAGR of 6.9% from 2020-2027.The growth of this market is estimated to grow owing to key driving factors such as increasing incidences of end-stage diseases and high development in government expenditure in the healthcare industry. However, the market is expected experiencing slow growth during the forecast period owing to a high cost of dialysis treatment in Asia Pacific region.
Key Market Segments
Based on product, the kidney disease market is segmented diagnosis and treatment. The diagnosis segment is further sub-segmented into blood tests, urine tests, imaging tests, and others. The treatment segment is further sub-segmented into dialysis, drug class, and others. The drug class is sub-divided into ACE inhibitors, angiotensin-2 receptor blockers, diuretics, and others.Based on end-user, the kidney disease market, is segmented into hospitals, diagnostic laboratories,and others.
Major Sources and Companies Listed
Some of the major primary and secondary sources forkidney disease market included in the report areChinese Renal Data Service, South Australian Health and Medical Research Institute (SAHMRI), and others.
Reasons to buy the report
- To understand the Asia Pacifickidney disease market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for kidney disease market
- Efficiently plan M&A and partnership deals in Asia Pacifickidney disease market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment formKidney disease market
- Obtain market revenue forecast for market by various segments from 2019 to 2027 in Asia Pacific region
ASIA PACIFICKIDNEY DISEASE MARKET SEGMENTATION
· Diagnosis
o Blood Tests
o Urine Tests
o Imaging Tests
o Others
· Treatment
o Dialysis
o Others
o Drug Class
§ ACE Inhibitors
§ Angiotensin-II Receptor Blockers
§ Diuretics
§ Others
· Hospitals
· Diagnostic Laboratories
· Others
By Country
· Asia Pacific
o Japan
o China
o India
o South Korea
o Australia
Company Profiles
- Abbott
- F. Hoffmann-La Roche Ltd
- AbbVieInc
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline plc
- Sysmex Corporation
- Siemens AG